News coverage about Viveve Medical (NASDAQ:VIVE) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viveve Medical earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.5261980727548 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Viveve Medical (NASDAQ:VIVE) traded up $0.04 during trading on Thursday, reaching $4.25. 4,048 shares of the company’s stock traded hands, compared to its average volume of 276,154. The firm has a market cap of $131.40, a price-to-earnings ratio of -1.97 and a beta of -0.79. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. Viveve Medical has a 1 year low of $3.30 and a 1 year high of $11.16.
Several equities research analysts recently commented on the stock. Mizuho restated a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research report on Thursday, February 1st. Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. Northland Securities assumed coverage on shares of Viveve Medical in a research report on Friday, January 5th. They issued an “outperform” rating and a $8.00 price target for the company. Finally, ValuEngine downgraded shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Viveve Medical has a consensus rating of “Buy” and an average target price of $10.00.
ILLEGAL ACTIVITY NOTICE: “Viveve Medical (VIVE) Receiving Somewhat Favorable Press Coverage, Study Shows” was published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://baseballnewssource.com/2018/03/15/viveve-medical-vive-receiving-somewhat-favorable-press-coverage-study-shows/2037821.html.
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.